CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH PATENT...Patent License Agreement • June 14th, 2024 • Camp4 Therapeutics Corp • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of October 23, 2019 (the “EFFECTIVE DATE”), is between the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, having a principal office at 455 Main Street, Cambridge, MA 02142 and CAMP4 Therapeutics Corporation (“COMPANY”), a Delaware corporation, having a principal place of business at One Kendall Square, Building 1400 West, Suite B14301, 3rd Floor, Cambridge, MA 02139.
LEASE AGREEMENTLease Agreement • September 20th, 2024 • Camp4 Therapeutics Corp • Pharmaceutical preparations • Massachusetts
THIS LEASE AGREEMENT (this “Lease”) is made as of this 3 day of October, 2019, between ARE-MA REGION NO 59, LLC, a Delaware limited liability company (“Landlord”), and CAMP4 THERAPEUTICS CORPORATION, a Delaware corporation (“Tenant”).
LEASE 4888 PEARL EAST CIRCLE Boulder, CO BCSP PEARL EAST PROPERTY LLC, a Delaware limited liability company as Landlord, and CAMP4 THERAPEUTICS CORPORATION, a Delaware corporation as Tenant.Lease • September 20th, 2024 • Camp4 Therapeutics Corp • Pharmaceutical preparations • Colorado
This Lease (the “Lease”), dated as of the Execution Date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between BCSP PEARL EAST PROPERTY LLC, a Delaware limited liability company (“Landlord”), and CAMP4 THERAPEUTICS CORPORATION, a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED First AMENDMENT to Patent License AgreementPatent License Agreement • June 14th, 2024 • Camp4 Therapeutics Corp • Pharmaceutical preparations • Massachusetts
This First Amendment to the Patent License Agreement (this “AMENDMENT”) is entered into as of December 14, 2021 (the “AMENDMENT EFFECTIVE DATE”), by and between the Whitehead Institute for Biomedical Research, a Delaware corporation having a principal office at 455 Main Street, Cambridge, MA 02142 (“WHITEHEAD”), and CAMP4 Therapeutics Corporation, a Delaware corporation, having a principal place of business at One Kendall Square Building 1400 West, 3rd Floor, Cambridge, MA 02139 (“COMPANY”) (together with WHITEHEAD, the “Parties” and each individually a “Party”), and amends that certain Patent License Agreement, dated as of October 23, 2019, by and between WHITEHEAD and COMPANY (the “Agreement”). Capitalized terms used in this AMENDMENT but not defined shall have the meanings set forth in the Agreement.
ContractCamp4 Therapeutics Corp • September 20th, 2024 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Second AMENDMENT To Patent License AgreementPatent License Agreement • June 14th, 2024 • Camp4 Therapeutics Corp • Pharmaceutical preparations • Massachusetts
This Second Amendment to the Patent License Agreement (this “SECOND AMENDMENT”) is entered into as of November 7, 2023 (the “SECOND AMENDMENT EFFECTIVE DATE”), by and between the Whitehead Institute for Biomedical Research, a Delaware corporation having a principal office at 455 Main Street, Cambridge, MA 02142 (“WHITEHEAD”), and CAMP4 Therapeutics Corporation, a Delaware corporation, having a principal place of business at One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139 (“COMPANY”) (together with WHITEHEAD, the “Parties” and each individually a “Party”), and amends the Patent License Agreement dated as of October 23, 2019, and first amended as of December 14, 2021, by and between WHITEHEAD and COMPANY (the “Agreement”; [***]). Capitalized terms used in this SECOND AMENDMENT but not defined shall have the meanings set forth in the Agreement.
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 20th, 2024 • Camp4 Therapeutics Corp • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 3, 2022, by and among Camp4 Therapeutics Corporation, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
